Biologics and biosimilars litigation update
Return to work: key issues for life sciences
par Helen Farr et Adrian Toutoungi
Private equity investment in life sciences sector
Exploring some of the potential benefits and challenges for life sciences companies considering PE investment.
par plusieurs auteurs
4 de 6 Publications
Licensing out: Try not to get benched
par Colin McCall et Justyna Ostrowska
Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents
par plusieurs auteurs
IP: Licensing and insolvency
par plusieurs auteurs
UK increases scrutiny of tech and life sciences deals
Mergers and acquisitions in the tech and life sciences sectors may be subject to closer scrutiny by the UK competition authority and by the UK government in future.
par Paolo Palmigiano
6 de 6 Publications
US buys up entire stock of remdesivir
Time to intervene?
Arbitration for life sciences companies
par plusieurs auteurs
Patents diary June 2020: UK Supreme Court holds Regeneron's transgenic mice patents invalid
par Dr Paul England